Trending NewsTrending NewsNASDAQ:EPRX Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis $7.63 +0.21 (+2.83%) Closing price 04:00 PM EasternExtended Trading$7.67 +0.04 (+0.47%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get EPRX alerts:Sign Up Key Stats Today's Range$7.20▼$7.6750-Day Range$6.34▼$9.1052-Week Range$5.63▼$9.32Volume476,714 shsAverage Volume624,811 shsMarket Capitalization$513.04 millionP/E RatioN/ADividend YieldN/APrice Target$17.17Consensus RatingModerate Buy Company Overview Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability. Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee. The company’s research has also included locally delivered treatments for gastrointestinal and other inflammatory conditions, including programs designed to address ulcerative colitis and related diseases. Founded in 2011 and headquartered in Victoria, British Columbia, Eupraxia conducts research and clinical development activities through international collaborations and clinical programs. Its shares trade on the Nasdaq Capital Market under the symbol EPRX.AI Generated. May Contain Errors. Read More Eupraxia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreEPRX MarketRank™: 2.63465886421 of 5 starsEupraxia Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 277th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEupraxia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEupraxia Pharmaceuticals has a consensus price target of $17.17, representing about 125.0% upside from its current price of $7.63.Amount of Analyst CoverageEupraxia Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eupraxia Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Eupraxia Pharmaceuticals are expected to decrease in the coming year, from ($0.90) to ($1.02) per share.Price to Book Value per Share RatioEupraxia Pharmaceuticals has a P/B Ratio of 5.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eupraxia Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.29% of the float of Eupraxia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 10.36, which indicates bearish sentiment.Change versus previous monthShort interest in Eupraxia Pharmaceuticals has recently decreased by 4.47%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEupraxia Pharmaceuticals does not currently pay a dividend.Dividend GrowthEupraxia Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.31 News SentimentEupraxia Pharmaceuticals has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Eupraxia Pharmaceuticals this week, compared to 3 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsEupraxia Pharmaceuticals has minimal institutional ownership at this time.Read more about Eupraxia Pharmaceuticals' insider trading history. Receive EPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPRX Stock News HeadlinesEupraxia Pharmaceuticals Establishes $125 Million At-The-Market Offering ProgramNovember 10 at 6:15 PM | marketscreener.comMEupraxia Pharmaceuticals Files November 10 Form 6-K With Interim ResultsNovember 10 at 4:51 PM | tipranks.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Eupraxia Pharmaceuticals Establishes At-The-Market Offering ProgramNovember 10 at 4:16 PM | globenewswire.comEupraxia Pharmaceuticals Reports Third Quarter 2026 Financial ResultsNovember 10 at 4:01 PM | globenewswire.comEupraxia Pharmaceuticals (EPRX) Has a New Rating from RBC CapitalNovember 10 at 8:13 AM | theglobeandmail.comRBC Initiates Eupraxia Pharmaceuticals at Outperform, Speculative Risk With $14 Price TargetNovember 9 at 5:07 PM | marketscreener.comMEupraxia Pharmaceuticals (NASDAQ:EPRX) Cut to "Strong Sell" at Wall Street ZenNovember 8 at 1:07 AM | americanbankingnews.comSee More Headlines EPRX Stock Analysis - Frequently Asked Questions How have EPRX shares performed this year? Eupraxia Pharmaceuticals' stock was trading at $7.55 on January 1st, 2026. Since then, EPRX shares have increased by 1.1% and is now trading at $7.63. How were Eupraxia Pharmaceuticals' earnings last quarter? Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) issued its earnings results on Tuesday, November, 10th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.03. Who are Eupraxia Pharmaceuticals' major shareholders? Eupraxia Pharmaceuticals' top institutional investors include Beutel Goodman & Co Ltd. (5.43%), Cibc World Market Inc. (0.33%) and China Universal Asset Management Co. Ltd.. How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/10/2026Last Earnings11/10/2026Next Earnings (Estimated)11/10/2026Stifel 2026 Healthcare Conference 202611/10/2026Analyst Day 202611/13/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, EPRX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EPRX Previous SymbolNASDAQ:EPRX CIK1581178 Webwww.eupraxiapharma.com Phone250-590-3968FaxN/AEmployees49Year Founded2012Price Target and Rating Average Price Target for Eupraxia Pharmaceuticals$17.17 High Price Target$25.00 Low Price Target$11.00 Potential Upside/Downside+125.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-63.97% Return on Assets-43.32% Debt Debt-to-Equity Ratio0.02 Current Ratio16.00 Quick Ratio16.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book5.41Miscellaneous Outstanding Shares67,240,000Free FloatN/AMarket Cap$513.04 million OptionableN/A Beta1.04 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:EPRX) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersBlack Friday Bombshell (for traders)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
